{"analyses":[{"ciLowerLimit":"0.70","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.99","estimateComment":"The HR and 95% confidence interval (CI) was based on a stratified Cox proportional hazards regression model, stratified by baseline Eastern Cooperative Oncology Group (ECOG) performance status, region and liver metastases as per IWRS.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.04","paramType":"Hazard Ratio (HR)","paramValue":"0.83","statisticalMethod":"Stratified log-rank test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.0","upperLimit":"12.1","value":"11.1"},{"groupId":"OG001","lowerLimit":"8.3","upperLimit":"10.6","value":"9.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"387"}],"units":"Participants"}],"description":"The OS was defined as time from the date of randomization to the date of death due to any cause. Participants who did not have a date of death recorded at the time of the final analysis were censored at the last known time that the participant was alive. The median OS was measured using Kaplan-Meier technique.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were treated with irinotecan liposome injection 50 mg/m\\^2 followed by oxaliplatin 60 mg/m\\^2, followed by LV 400 mg/m\\^2 and then 5-FU 2400 mg/m\\^2 IV infusion on Days 1 and 15 of each 28-day cycle until disease progression, death, unacceptable study treatment-related toxicity or withdrawal of consent.","id":"OG000","title":"NALIRIFOX"},{"description":"Participants were treated with nab-paclitaxel 125 mg/m\\^2 followed by gemcitabine 1000 mg/m\\^2 IV on Days 1, 8 and 15 of each 28-day cycle until disease progression, death, unacceptable study treatment-related toxicity or withdrawal of consent.","id":"OG001","title":"Nab-paclitaxel+Gemcitabine"}],"paramType":"MEDIAN","populationDescription":"The ITT population consisted of all randomized participants to whom study treatment was assigned by randomization.","reportingStatus":"POSTED","timeFrame":"Assessments performed at baseline (within 28 days before start of study treatment), every 8 weeks after first dose, end of treatment (EoT) visit, then every 2 months thereafter up to primary completion date (PCD) of 23 July 2022 (maximum of 893 days)","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"months"}